CLINICAL_TRIALS ClinicalTrials.gov record update

Safety and Preliminary Pharmacodynamics of Allogeneic CD19/BCMA-Targeted CAR-γδT Cell Therapy in Patients With Relapsed/Refractory Autoimmune Diseases

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT07490275
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:28:09.282459+00:00
Published At: 2026-03-24T00:00:00+00:00
Record Updated At: 2026-03-24
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Refractory/Relapsed Systemic Lupus Erythematosus", "Refractory / Relapsed / Progressive Systemic Sclerosis", "Refractory / Relapsing / Progressive Inflammatory Myopathy", "Refractory / Relapsed Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis", "Refractory / Relapsed Connective Tissue Disease-Associated Thrombocytopenia"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2026-03-24"
protocolSection.identificationModule.nctId: "NCT07490275"
protocolSection.identificationModule.officialTitle: "Safety and Preliminary Pharmacodynamics of Allogeneic CD19/BCMA-Targeted CAR-\u03b3\u03b4T Cell Therapy in Patients With Relapsed/Refractory Autoimmune Diseases"
protocolSection.statusModule.overallStatus: "NOT_YET_RECRUITING"
protocolSection.designModule.phases: ["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.